• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

重新审视经静脉膈神经刺激治疗中枢性睡眠呼吸暂停和心力衰竭:临床试验分析中的新进展

Revisiting Transvenous Phrenic Nerve Stimulation in Central Sleep Apnoea and Heart Failure: Emerging Innovations in Clinical Trials Analysis.

作者信息

Bekfani Tarek, Abraham Joseph D, Abraham William T

机构信息

Department of Cardiology and Angiology, University Hospital Magdeburg Magdeburg, Germany.

Department of Internal Medicine, The Jewish Hospital, Cincinnati OH, US.

出版信息

Card Fail Rev. 2025 Aug 20;11:e22. doi: 10.15420/cfr.2025.07. eCollection 2025.

DOI:10.15420/cfr.2025.07
PMID:40901558
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12400169/
Abstract

Central sleep apnoea (CSA) is a common comorbidity in patients with heart failure. Due to its insidious and chronic nature, CSA often remains unrecognised. Patients with CSA typically present with symptoms, such as daytime fatigue, recurrent heart failure decompensations and cardiac arrhythmias. Although the pathophysiology of CSA is not yet fully understood, the most widely accepted theory suggests that fluctuations in PaCO levels, particularly crossing the apnoeic threshold, play a central role in its development. CSA is associated with various changes, including activation of the sympathetic nervous system, neurohormonal disturbances and haemodynamic perturbations, all of which contribute to increased morbidity and mortality. Transvenous phrenic nerve stimulation (TPNS) has been demonstrated to be a safe and effective therapy for reducing the apnoea-hypopnoea index and improving both left ventricular ejection fraction and quality of life in patients with CSA. These benefits have been validated in randomised clinical trials (RCTs). New methods of analysing RCTs were recently introduced. Applying the win ratio method in a post hoc analysis of the primary RCTs evaluating TPNS suggested that TPNS may also contribute to reduced mortality and fewer heart failure hospitalisations. In this article we explore the pathophysiology of CSA and evaluate the existing evidence on therapeutic options, with a particular focus on TPNS.

摘要

中枢性睡眠呼吸暂停(CSA)是心力衰竭患者常见的合并症。由于其隐匿性和慢性特点,CSA常常未被识别。CSA患者通常表现出如日间疲劳、反复的心衰失代偿和心律失常等症状。尽管CSA的病理生理学尚未完全明确,但最广泛接受的理论认为,动脉血二氧化碳分压(PaCO)水平的波动,尤其是超过呼吸暂停阈值,在其发病过程中起核心作用。CSA与多种变化相关,包括交感神经系统激活、神经激素紊乱和血流动力学扰动,所有这些都导致发病率和死亡率增加。经静脉膈神经刺激(TPNS)已被证明是一种安全有效的治疗方法,可降低呼吸暂停低通气指数,并改善CSA患者的左心室射血分数和生活质量。这些益处已在随机临床试验(RCT)中得到验证。最近引入了分析RCT的新方法。在对评估TPNS的主要RCT进行事后分析时应用胜率法表明,TPNS可能还有助于降低死亡率和减少因心力衰竭住院的次数。在本文中,我们探讨了CSA的病理生理学,并评估了现有治疗选择的证据,特别关注TPNS。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d518/12400169/985f32bd7f85/cfr-11-e22-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d518/12400169/23223996dc15/cfr-11-e22-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d518/12400169/4f15a6e2a986/cfr-11-e22-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d518/12400169/72ece5acc659/cfr-11-e22-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d518/12400169/3a3928042408/cfr-11-e22-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d518/12400169/985f32bd7f85/cfr-11-e22-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d518/12400169/23223996dc15/cfr-11-e22-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d518/12400169/4f15a6e2a986/cfr-11-e22-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d518/12400169/72ece5acc659/cfr-11-e22-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d518/12400169/3a3928042408/cfr-11-e22-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d518/12400169/985f32bd7f85/cfr-11-e22-g005.jpg

相似文献

1
Revisiting Transvenous Phrenic Nerve Stimulation in Central Sleep Apnoea and Heart Failure: Emerging Innovations in Clinical Trials Analysis.重新审视经静脉膈神经刺激治疗中枢性睡眠呼吸暂停和心力衰竭:临床试验分析中的新进展
Card Fail Rev. 2025 Aug 20;11:e22. doi: 10.15420/cfr.2025.07. eCollection 2025.
2
Non-invasive positive pressure ventilation for central sleep apnoea in adults.成人中枢性睡眠呼吸暂停的无创正压通气。
Cochrane Database Syst Rev. 2022 Oct 24;10(10):CD012889. doi: 10.1002/14651858.CD012889.pub2.
3
Pharmacological treatment for central sleep apnoea in adults.成人中枢性睡眠呼吸暂停的药物治疗。
Cochrane Database Syst Rev. 2023 Feb 27;2(2):CD012922. doi: 10.1002/14651858.CD012922.pub2.
4
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
5
Treatment of central sleep apnea in adults: an American Academy of Sleep Medicine clinical practice guideline.成人中枢性睡眠呼吸暂停的治疗:美国睡眠医学会临床实践指南
J Clin Sleep Med. 2025 Aug 18. doi: 10.5664/jcsm.11858.
6
Win ratio analysis of transvenous phrenic nerve stimulation to treat central sleep apnoea in heart failure.经静脉膈神经刺激治疗心力衰竭中枢性睡眠呼吸暂停的胜率分析
ESC Heart Fail. 2025 Feb;12(1):80-86. doi: 10.1002/ehf2.15074. Epub 2024 Oct 18.
7
Antidepressants for pain management in adults with chronic pain: a network meta-analysis.抗抑郁药治疗成人慢性疼痛的疼痛管理:一项网络荟萃分析。
Health Technol Assess. 2024 Oct;28(62):1-155. doi: 10.3310/MKRT2948.
8
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.系统性药理学治疗慢性斑块状银屑病:网络荟萃分析。
Cochrane Database Syst Rev. 2021 Apr 19;4(4):CD011535. doi: 10.1002/14651858.CD011535.pub4.
9
Systemic pharmacological treatments for chronic plaque psoriasis: a network meta-analysis.慢性斑块状银屑病的全身药理学治疗:一项网状荟萃分析。
Cochrane Database Syst Rev. 2017 Dec 22;12(12):CD011535. doi: 10.1002/14651858.CD011535.pub2.
10
Determinants of transvenous phrenic nerve stimulation-induced improvements in left ventricular function in central sleep apnea and heart failure.
Sleep. 2025 Aug 14;48(8). doi: 10.1093/sleep/zsaf085.

本文引用的文献

1
Win ratio analysis of transvenous phrenic nerve stimulation to treat central sleep apnoea in heart failure.经静脉膈神经刺激治疗心力衰竭中枢性睡眠呼吸暂停的胜率分析
ESC Heart Fail. 2025 Feb;12(1):80-86. doi: 10.1002/ehf2.15074. Epub 2024 Oct 18.
2
Transvenous phrenic nerve stimulation is associated with normalization of nocturnal heart rate perturbations in patients with central sleep apnea.经静脉膈神经刺激可使中枢性睡眠呼吸暂停患者的夜间心率紊乱正常化。
Sleep. 2023 Sep 8;46(9). doi: 10.1093/sleep/zsad166.
3
Transcatheter Repair for Patients with Tricuspid Regurgitation.
经导管三尖瓣反流修复术治疗患者。
N Engl J Med. 2023 May 18;388(20):1833-1842. doi: 10.1056/NEJMoa2300525. Epub 2023 Mar 4.
4
Transvenous phrenic nerve stimulation for the treatment of central sleep apnea reduces episodic hypoxemic burden.经静脉膈神经刺激治疗中枢性睡眠呼吸暂停可减轻间歇性低氧血症负担。
Int J Cardiol. 2023 May 1;378:89-95. doi: 10.1016/j.ijcard.2023.02.041. Epub 2023 Feb 24.
5
Design of the remedē System Therapy (rēST) study: A prospective non-randomized post-market study collecting clinical data on safety and effectiveness of the remedē system for the treatment of central sleep apnea.rēST 研究的设计:一项前瞻性非随机上市后研究,旨在收集 remedē 系统治疗中枢性睡眠呼吸暂停的安全性和有效性的临床数据。
Sleep Med. 2022 Dec;100:238-243. doi: 10.1016/j.sleep.2022.08.026. Epub 2022 Sep 6.
6
Transvenous Phrenic Nerve Stimulation for Central Sleep Apnea.经静脉膈神经刺激治疗中枢性睡眠呼吸暂停。
Am J Cardiol. 2022 Oct 1;180:155-162. doi: 10.1016/j.amjcard.2022.06.038. Epub 2022 Jul 30.
7
The SGLT2 inhibitor empagliflozin in patients hospitalized for acute heart failure: a multinational randomized trial.钠-葡萄糖协同转运蛋白 2 抑制剂恩格列净治疗急性心力衰竭住院患者的多中心随机试验。
Nat Med. 2022 Mar;28(3):568-574. doi: 10.1038/s41591-021-01659-1. Epub 2022 Feb 28.
8
2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure.2021年欧洲心脏病学会急性和慢性心力衰竭诊断与治疗指南。
Eur Heart J. 2021 Sep 21;42(36):3599-3726. doi: 10.1093/eurheartj/ehab368.
9
Transvenous Phrenic Nerve Stimulation for Treatment of Central Sleep Apnea: Five-Year Safety and Efficacy Outcomes.经静脉膈神经刺激治疗中枢性睡眠呼吸暂停:五年安全性和疗效结果
Nat Sci Sleep. 2021 Apr 29;13:515-526. doi: 10.2147/NSS.S300713. eCollection 2021.
10
Transvenous phrenic nerve stimulation improves central sleep apnea, sleep quality, and quality of life regardless of prior positive airway pressure treatment.经静脉膈神经刺激可改善中枢性睡眠呼吸暂停,无论先前是否接受过正压通气治疗,均能改善睡眠质量和生活质量。
Sleep Breath. 2021 Dec;25(4):2053-2063. doi: 10.1007/s11325-021-02335-x. Epub 2021 Mar 20.